The likelihood that a participant in a randomized, controlled trial receives laquinimod or placebo to treat relapsing-remitting multiple sclerosis (RRMS) could explain the differences in study results, according to recent research.
There are now more than a dozen medications approved for the treatment of relapsing multiple sclerosis, a treatment pending approval for primary progressive, and very early signs of hope for secondary progressive. As a result there was plenty of optimism at ECTRIMS as it left London and prepared for Paris next year.
As Ocrelizumab moves its way through the approval process for patients with primary progressive multiple sclerosis, data has been released on a trial for a potential treatment for the secondary progressive form.
When a medication is approved the data from that time can sometimes be of more value than the trials leading up to the approval. For Aubagio there was a recent study done looking at patient satisfaction and other issues following the approval.
With many new drug discoveries and medical devices int he field of advanced heart failure, Larry Allen, MD, MHS and his team are working to create patient decision support tools to help them navigate any challenges.
Previous research has shown that prolonged-release fampridine (PR-FAM) can help walking ability in patients with multiple sclerosis (MS), however, it’s unclear whether those findings are clinically significant.